Introduction
Lung cancer is the most common cause of cancer deaths in the United States and other developed countries. It accounts for approximately 30% of all cancer deaths and in the United States alone 4150 000 people die of lung cancer every year (Parker et al., 1997) . Lung tumors are divided into two major types, NSCLC and SCLC. 80% of lung cancer incidences are attributed to the NSCLC type, while SCLC accounts for the rest 20% of cases. The overall 5-year survival rate for patients diagnosed with NSCLC is 10 ± 15%, while patients diagnosed with SCLC have an even worse prognosis with a 5-year survival rate of 55% (Ginsberg et al., 1997; Ihde et al., 1997) . Although, SCLC is initially highly responsive to radiation and chemotherapy (50 ± 90%), most patients tend to relapse with highly resistant disease within a year of treatment (Ihde et al., 1997) . Most patients diagnosed with SCLC have regional lymph-node involvement or disseminated disease at the time of initial diagnosis (Ihde, 1992) , which strongly correlates with the poor prognosis observed for these patients. Thus, the problem with the management of lung cancer can be attributed to the lack of reliable early detection methods and the inadequacies of current treatment protocols. This has warranted the eorts towards identi®cation of new molecular targets for designing more reliable diagnostic methods and novel therapeutic protocols for the treatment of this malignancy.
SCLC tumors are distinguished by their neuroendocrine phenotype and frequently stain for neuroendocrine markers such as neuron-speci®c enolase, chromogranin, and synsptophysin (Guinee et al., 1994) . SCLC cells are also found to secrete several autocrine growth factors and hormones including gastrin-releasing peptide, neurotensine, vasopressin, and cholecystokinin (Kalemkerian, 2000; Williams, 1997) . Some of the autocrine growth factors have been used as prognostic markers of this disease with varying levels of success and reliability (Feld et al., 2000) . However, their use as diagnostic and therapeutic targets has not been very successful (Kalemkerian, 2000) . Thus the need of new reliable and eective targets for the early detection and management of this malignancy is more than ever. It has been well documented that cancer cells go through a lot of genetic and epigenetic changes (Lengauer et al., 1998; Williams, 1997) , which is suggested to bring about dramatic changes in the gene expression pro®les of these cells. The past decade has seen the development of several technologies for pro®ling these changes in gene expression, including dierential and subtractive hybridization, dierential display, SAGE, and microarrays (Gray and Collins, 2000) . These approaches have proven to be extremely useful in providing a comprehensive look at the biology of various cancers as well as in the identi®cation of new targets for the development of novel therapeutic approaches for the treatment of these cancers (Backert et al., 1999; Nacht et al., 1999; Nocito et al., 2001; Ono et al., 2000; Sgroi et al., 1999; Wang et al., 2000; Xu et al., 2000; Yang et al., 1999) . Recent studies have documented a large number of genetic alterations present in SCLC (Girard et al., 2000; Wistuba et al., 2000a,b) , which is indicative of possible changes in the gene expression pro®le. However, little has been done in exploring these changes in SCLC and the only study reported to date was very limited in scope and was designed to address the dierences between the SCLC subtypes at the molecular level (Anbazhagan et al., 1999) .
This study was undertaken to carryout a comprehensive analysis of the changes in gene expression in SCLC and was speci®cally focused towards identi®ca-tion of genes that are dierentially over-expressed in SCLC. To accomplish this we used a combination of technologies including suppression subtractive hybridization (SSH) for cDNA subtraction (Diatchenko et al., 1996) , high-density cDNA microarray and quantitative real-time RT ± PCR. Several recent reports have shown the successful use of similar technologies in identifying novel and previously unknown genes found to be dierentially expressed in breast, prostate, head and neck, and lung squamouscell carcinoma (Villaret et al., 2000; Wang et al., 2000; Xu et al., 2000; Yang et al., 1999) . Here we report the identi®cation of 209 genes that are dierentially over-expressed in SCLC compared to normal tissues and the initial characterization of nine of these genes. Further characterization of these nine genes and other genes identi®ed in this study will be helpful in de®ning a panel of diagnostic and therapeutic targets for SCLC and better our understanding into the biology of this malignancy.
Results

Generation and characterization of SCLC specific cDNA libraries
To enrich for genes preferentially expressed in SCLC, we generated four SCLC tumor speci®c cDNA libraries using the suppression subtractive hybridization method (Diatchenko et al., 1996) . These subtracted libraries are referred to as SCL1, SCL2, SCL3 and SCL4 (for details, see materials and methods). The initial characterization of these subtracted libraries was done by estimating the eciency of subtraction and sequencing of 48 ± 96 randomly picked clones from each library. The eciency of subtraction was determined by comparing the abundance of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNAs before and after subtraction. GAPDH is a good representative for constitutively expressed genes, which are highly abundant in most tissues. Figure 1 shows the depletion of GAPDH from the subtracted cDNA mixture for the SCL3 library. For the unsubtracted cDNAs, GAPDH speci®c PCR product is visible by the 23rd round of ampli®cation. However, in case of the subtracted cDNAs, the GAPDH speci®c PCR product is visible only after 33 rounds of ampli®cation. This is indicative of preferential depletion of GAPDH and most ubiquitously expressed genes from the subtracted cDNA mixture. Sequence analysis of 48 ± 96 randomly picked clones gave us a good estimation of the complexity of the subtracted libraries. Generally the libraries generated by the suppression subtractive hybridization method are of high complexity because of the normalization of highly abundant messages during hybridization. However, in case of the SCL2 subtracted cDNA library, we repeatedly recovered cDNAs for GRP and ASH1, which are known to be over-expressed in SCLC (Ball et al., 1993; Yamaguchi et al., 1983) . Approximately 30% of the clones from this library contained cDNA inserts representing either of the two genes (data not shown). The repeated recovery of these genes was an indication of successful subtraction for enriching genes dierentially expressed in SCLC. However, it also meant that the SCL2 library had a set of highly redundant clones and was not complex enough to be screened further by microarray. To overcome this problem, two additional subtracted libraries, SCL3 and SCL4, were constructed using a driver cDNA pool for hybridization that included the cDNAs for GRP and ASH1 in addition to the nine normal tissues used for the SCL2 library (see Materials and methods). The inclusion of the GRP and ASH1 cDNAs in the driver pool decreased the percentage of clones that represented these two genes to around 5% in the SCL3 and SCL4 libraries. Thus by spiking in the cDNAs for the two highly abundant genes we were able to generate libraries that were of sucient complexity that could be exploited further by cDNA microarray analysis.
cDNA microarray analysis
Twenty-four thousand randomly selected cDNA clones from SCL1, SCL3, and SCL4 subtracted libraries were PCR ampli®ed and arrayed onto 32 replicate glass slides (microarrays). Each microarray was then analysed with a pair of Cy3 and Cy5¯uorescent dye Figure 1 Subtraction eciency as determined by depletion of GAPDH from the subtracted cDNA population. Equal amounts of subtracted and unsubtracted cDNAs were subjected to PCR ampli®cation for the indicated number of cycles using GAPDH gene speci®c primers. PCR products were run on a 1% agarose gel and stained with ethidium bromide. M, molecular weight marker labeled sample to determine the expression pro®les of the cDNA clones in the tumor and normal tissue represented by the labeled samples. In all 32 labeled sample pairs (Table 1) were used to get a comprehensive picture of the expression of the cDNAs in a variety of tumor and normal tissues. Microarray fabrication, generation of the Cy3 and Cy5 labeled cDNA samples, hybridization, imaging, quantitation and normalization of the microarray expression data was performed by Rosetta Inpharmatics (Kirkland, WA, USA) (see Material and methods). To identify genes that are dierentially over-expressed in SCLC the mean¯uor-escent intensity of a given cDNA clone in the eight SCLC samples was compared with its mean¯uorescent intensity in all the normal tissue samples. Figure 2 illustrates the expression pro®les of all the cDNA clones on the chip, where the mean¯uorescent intensity of the eight SCLC samples was compared with the mean¯uorescent intensity of the thirty-two normal tissue samples. Clones that have the highest likelihood of being dierentially over-expressed in SCLC are indicated to be within the encircled area. In all 490 cDNA clones with a ratio of two or more between the SCLC and normal tissue samples were identi®ed and sequenced for further analysis. Sequence analysis showed that the 490 clones formed 209 unique cDNA contigs, possibly representing 209 unique genes. Of the 209 cDNA contigs 123 were found to be previously known genes and the remaining 86 represented novel gene sequences. Table 2 summarizes the identity and the number of time each gene was recovered by the microarray analysis.
Identification of cDNAs differentially expressed in small cell lung cancer
The objective of this study was to identify genes that are not only dierentially over-expressed in SCLC but also have very little to no expression in majority of normal tissues. To identify such genes we visually examined the expression of each of the 209 genes, identi®ed from the initial analysis, in each tumor and normal tissue samples tested. We looked for genes that showed reasonable expression in SCLC samples while having very little to no signal in majority of the normal tissue samples. Based on these criteria, we were able to come up with 43 genes for further characterization. Here we are reporting the characterization of nine genes with the most promising SCLC tumor to normal tissue expression pro®le, these include seven known and two novel genes. The identity of the nine genes with their corresponding candidate designation is summarized in Table 3 . Also, listed is the number of times each of these genes was recovered from the microarray analysis and the fold over-expression of these genes in SCLC tumors compared to normal tissue as determined by both microarray and quantitative real-time RT ± PCR analysis.
Microarray expression profile of genes over-expressed in SCLC
The microarray expression pro®les of the nine genes described in Table 3 are shown in Figure 3 , with the Cy3 and Cy5 labeled sample pairs listed on the left of each panel (also refer to Table 1 ). The expression level of each gene in a given sample is shown as pseudo color image. Also, listed are the fold over-expression values for sample pairs where it was observed that the given gene was over-expressed by two-fold or more in the SCLC tumor sample (Cy3) compared to the corresponding normal tissue sample (Cy5). It is evident from the microarray images that these genes are overexpressed in SCLC tumors compared to majority of the normal tissues. In some cases expression is also seen in adenocarcinoma and/or squamous cell carcinoma. L978P, L580S and L1435P are members of the SOX family genes (Wegner, 1999) . Although, they belong to the same gene family their expression levels and distribution in lung tumors are very dierent ( Figure  3 ). L978P is highly dierentially expressed not only in SCLC but also in lung adenocarcinoma and squamous cell carcinoma. L580S and L1435P on the other hand are expressed only in a select few SCLC and squamous cell carcinomas. L1437P, L1438P, and L1439P are highly over-expressed in majority of the SCLC samples ( Figure 3 ). Detectable expression of these genes can also be seen in various hematopoetic tissues especially activated T-cells and bone marrow. L1437P is also expressed in normal stomach, while L1438P expression can be observed in normal tonsil (Figure 3 ). L986P and L1423P are not only expressed in SCLC tumors but also in the metastatic atypical carcinoid tumor, while L1424P expression is seen only in the metastatic atypical carcinoid tumor. L986P and L1423S expression can also be detected in normal neurological tissues such as brain and pituitary gland, this is not surprising as SCLC are classi®ed as neuroendocrine tumors and are known to express several neuroendocrine markers.
Quantitative real-time PCR analysis
For those genes that were identi®ed as being overexpressed in SCLC by microarray expression pro®ling, further analysis was performed using quantitative realtime RT ± PCR analysis. This was done to con®rm the expression pro®les of the genes by an independent method and to get additional quantitative information regarding the expression of these genes in both tumor and a variety of normal tissues. The real-time RT ± PCR analysis was carried out using a panel of SCLC primary tumor and cell lines, a metastatic atypical carcinoid, pools of adenocarcinoma and squamouscell carcinoma, normal lung, and other normal tissues (see legend for Figure 4) . As evident from the results of the real-time RT ± PCR analysis ( Figure 4 ) the overall expression pro®les for these genes correlated well with their microarray expression pro®les (Figure 3) .
Similar to the microarray expression data L978P is expressed in all of the SCLC samples, atypical carcinoid, and the adenocarcinoma pool present on the real-time RT ± PCR panel ( Figure 4A ). L580S is expressed in only three of the eight SCLC samples, with signi®cant expression also seen in normal brain, pituitary gland, spinal cord, trachea, and salivary gland ( Figure 4A ). L1435P is expressed only in one of the SCLC samples as well as normal stomach ( Figure 4A ), which correlate well with its microarray expression (Figure 3) . L1437P, L1438P, and L1439P are expressed in majority of the SCLC tumors ( Figure 4B ). However, expression of these genes in the metastatic atypical carcinoid tumor was at a very negligible level. L1438P and L1439P expression can also be detected in bone marrow, which is again consistent with the microarray analysis results. Similar to the microarray results, the real-time RT ± PCR analysis showed that L986P and L1423P are over-expressed not only in SCLC tumors but also in the atypical carcinoid tumor ( Figure 4C ). Signi®cant levels of L986P and L1423P message are also detected in normal neurological tissues such as brain and pituitary gland. Real-time RT ± PCR analysis of L1424P shows that it is expressed not only in the atypical carcinoid as observed by microarray analysis ( Figure 4C ), but also in one of the primary SCLC tumors which was not detected by microarray analysis (Figure 3 ). This may be due to the higher sensitivity of real-time RT ± PCR technology in detecting low abundant messages.
Discussion
We have been successful in identifying 209 genes that are dierentially over-expressed in SCLC tumors. This Figure 3 Microarray analysis of genes dierentially over-expressed in SCLC. cDNA clones were PCR ampli®ed, arrayed onto 32 replicate glass slides, and analysed using 32 pairs of Cy3 or Cy5 labeled cDNA samples as indicated. The¯uorescence intensity for each sample is shown as pseudocolor image and corresponds to the level of expression of a given gene in the tissue represented by that sample. Also, listed are the fold dierential expression values for the Cy3 labeled sample over the Cy5 labeled sample in case of the SCLC sample pairs (Sample Pair #23 ± 30) was achieved using a combination of technologies, which included suppression subtractive hybridization for cDNA subtraction, high-density cDNA microarray and quantitative real-time RT ± PCR. Combination of subtractive hybridization and high-density cDNA microarrays has been well documented for identifying tumor speci®c genes in a variety of cancers (Kitahara et al., 2001) . A good indication for the success of this approach is the fact that several of the genes including GRP, ASH1, TOP2A and CEA are known to be highly expressed in SCLC tumors (Ball et al., 1993; Giaccone, 1994; Kim et al., 1992; Yamaguchi et al., 1983) . Another indication of the success of this approach was the identi®cation of a large number of genes that have been previously described to be associated with cancer. These include genes involved in cell ± cycle regulation, apoptosis, protein synthesis and degradation, transcription factors, and oncogenes among others (Table 2) . Quantitative real-time RT ± PCR was used to con®rm the expression of some of the target genes identi®ed by microarray analysis. This was used as an independent but complimentary approach to microarray expression analysis and provided us with an accurate quantitative picture of the expression of these genes in the target tissues. L978P, L580S and L1435P belong to the SOX protein family (Wegner, 1999) . These proteins contain a conserved DNA binding motif known as the HMG box, which is present in a large number of non-histone chromosomal proteins part of the HMG box superfamily. SOX proteins are involved in various aspects of early development during embryogenesis such as sex determination, neural development, lens development, chondrogenesis, and hemopoiesis (Wegner, 1999) . To our knowledge this is the ®rst report that describes the dierential expression of SOX genes in SCLC tumors. However, it should be noted that Gure et al. (2000) have earlier identi®ed SOX2, SOX3 and SOX21 as highly immunogenic SCLC tumor antigens by serological expression cloning approach. They showed presence of high-titer antibodies to SOX2, SOX3 and SOX21 in SCLC patient sera and suggested that these proteins could be potential cancer diagnostics and vaccine targets. It has also been recently reported that ectopic expression of SOX3 in chicken embryo ®broblasts can cause oncogenic transformation of these cells in culture (Xia et al., 2000) . These results suggest that members of SOX protein family can induce aberrant cell growth and may have the potential to induce oncogenic transformation in SCLC.
L1437P, L1438P and L1439P are all genes that are either directly or indirectly involved in the regulation of cell cycle. It has been well documented that disruptions in the normal process of cell cycle progression is a common feature shared by all cancers. L1437P is a novel member of the ubiquitin-conjugating enzyme E2 gene family. E2 enzymes are part of the ubiquitin-proteasome pathway for protein degradation and are a large family of ubiquitin-carrier proteins with dierent functions and substrate speci®cities (Hochstrasser, 1996) . The ubiquitin proteolytic pathway plays an essential role in the regulation of key cellular functions including the normal progression of cell cycle (Hochstrasser, 1996; Tannoch et al., 2000) . Several tumor suppressors such as p53 and oncogenes are also turned over by this pathway (Spataro et al., 1998) . It will be interesting to see which proteins this new member of the E2 enzyme family targets for degradation and whether up-regulation of L1437P expression causes tumor transformation. L1438P or pituitary tumor-transforming gene (PTTG) functions as an inhibitor of sister-chromatid separation Zou et al., 1999) . Over-expression of PTTG in NIH 3T3 cells induces transformation in vitro and tumor formation in vivo . This oncogenic activity is attributed to its function as overexpression of PTTG disrupts sister-chromatid separation and causes aneuploidy (Yu et al., 2000; Zou et al., 1999) . PTTG is over-expressed in multiple tumors, including pituitary adenomas, leukemia, lymphoma, lung, colon, breast and ovarian carcinomas Puri et al., 2001; Zhang et al., 1999) , making it an ideal therapeutic target for treating cancer. L1439P is the human homologue of the yeast NUF2 gene, which encodes a protein that is localized to the nuclear face of the spindle pole body (Osborne et al., 1994) . Disruption of NUF2 function in yeast results in cells arrested in mitosis, with shortened mitotic spindle and fully replicated DNA (Osborne et al., 1994) , suggesting a speci®c defect in chromosome segregation. As both L1438P and L1439P are required for the proper progression of cell division through mitosis it will be interesting to see if over-expression of these two genes contributes to the high rate of aneuploidy found in SCLC (Jackson-York et al., 1991; Oud et al., 1989; Travis et al., 1991) .
L1423P or collapsing response mediator protein-1 (CRMP-1) is one of the ®ve known members of the CRMP intracellular signaling phosphoproteins (Hamajima et al., 1996; Quinn et al., 1999) . CRMP proteins are involved in axonal guidance and neuronal dierentiation by mediating semaphorin/collapsing induced growth cone collapse (Quinn et al., 1999) . Several studies have shown the presence of autoantibodies against CRMP-3 and CRMP-5 in SCLC patients (Honnorat et al., 1999; Yu et al., 2001 ). It will be interesting to see if autoantibodies against CRMP-1 are also present in SCLC patients. Recently it was reported that CRMP-1 might be involved in cancer cell invasion (Shih et al., 2001) . Speci®cally it was shown that there is an inverse correlation between CRMP-1 expression and the invasive ability of lung adenocarcinoma cells. It was also reported that CRMP-1 is dierentially expressed in NSCLC tumors and the expression is related to the tumor stage, lymph node metastasis, and survival of the patients (Shih et al., 2001) . L986P and L1424P represent two novel cDNA sequences. Fulllength cloning of these genes and further characterization of their function will help us in determining their usefulness as cancer therapeutic targets and their role in the mechanisms of SCLC tumorigenesis.
By using cDNA subtraction and microarray expression pro®ling we have been able to take a comprehensive look at the changes in expression pattern of genes in SCLC. We report the identi®cation of several hundred dierentially expressed genes and the initial characterization of nine genes that are preferentially expressed in SCLC tumors. Further characterization of these nine genes and other genes identi®ed in this study will be helpful in de®ning a panel of diagnostic and therapeutic targets for SCLC and better our understanding into the biology of this malignancy.
Materials and methods
Tissue and RNA sources
Tumor and normal tissues samples were obtained from Cooperative Human Tissue Network (CHTN), National Disease Research Interchange (NDRI), and other clinical sources. SCLC tumor cell lines were obtained from American Type Culture Collection (ATCC). Total RNA was isolated from the tissue samples using Trizol total-RNA isolation kit (Invitrogen, Carlsbad, CA, USA). Poly(A) + RNA puri®ca-tion was carried out using Qiagen mRNA Puri®cation Kit a b (Qiagen Inc. Valencia, CA, USA). Some normal tissue total-RNA and poly(A) + RNA were purchased from Clontech (Palo Alto, CA, USA) and Invitrogen (Carlsbad, CA, USA).
Subtracted cDNA libraries
To enrich for genes preferentially expressed in SCLC four subtracted libraries were constructed using the PCR-Select cDNA Subtraction kit (Clontech Inc., Palo Alto, CA, USA). The SCL1 subtracted library was constructed using poly(A) + RNA from a single SCLC primary tumor sample as tester and a pool of eight normal tissue (lung, brain, kidney, liver, pancreas, skin, heart and spleen) poly(A) + RNA in equal amounts as driver. The SMART cDNA ampli®cation kit (Clontech Inc., Palo Alto, CA, USA) was used to synthesize and amplify the tester and driver cDNA. Two hundred ng of poly(A) + RNA for both tester and driver were used to synthesize the cDNA and ampli®cation was carried out for 24 cycles. The ampli®ed cDNA was puri®ed and 2 mg of ampli®ed cDNA for both tester and driver were then used for the construction of the SCL1 library using the PCR-Select cDNA Subtraction kit. The tester and driver cDNAs were blunt-ended with T4 polymerase and then digested with a mixture of four endonucleases including MscI, PvuII, DraI, and StuI. The digested tester cDNAs were ligated to adapter 1 and adapter 2R, provided with the PCR-Select cDNA Subtraction kit, in separate ligation reaction. The ligation reaction mixtures were incubated overnight at 168C. The subtractive hybridization of adapter-ligated testers with drivers was performed according to the PCR-Select cDNA Subtraction kit protocol, using a tester to driver ratio of 1 : 60. Two rounds of PCR ampli®cation were performed to complete the subtraction and amplify the subtracted cDNA fragments. The ®rst ampli®cation was performed as follows: 5 min adapter extension at 758C, then 948C/30 s, 668C/30 s and 728C/90 s for 27 cycles. The second PCR was performed with conditions of 948C/30 s, 688C/30 s and 728C/90 s for 12 cycles. The primers used for PCR were supplied with the PCR-Select cDNA Subtraction kit. The SCL2 subtracted library was constructed using the procedure essentially described above for the construction of the SCL1 library. Except that the poly(A) + RNA used for generating the tester cDNA was derived from an independent SCLC tumor sample. Also, the cDNA was synthesized straight from 2 mg poly(A) + RNA using reagents included in the PCR-Select cDNA Subtraction kit, without the initial cDNA ampli®ca-tion that was carried out in case of the SCL1 library construction. The SCL3 and SCL4 libraries were constructed using the procedure essentially as described above for the construction of the SCL2 library. Except that the driver cDNA pool was spiked with cDNAs for gastrin-releasing peptide (GRP) and achaete-scute homolog 1 (ASH1), two highly abundant genes present in the SCL2 library, during the hybridization step. For the SCL3 library the hybridization was carried out at a tester to driver ratio of 1 : 60 and for the SCL4 library the ratio was 1 : 80. Cloning and sequencing analysis of the subtracted cDNA library.
Secondary PCR products generated from the subtracted cDNAs were subcloned into the pCR2.1 TOPO T/A cloning vector (Invitrogen, Carlsbad, CA, USA). The ligated cDNAs were then transformed into DH10B electro-competent cells by electroporation (Invitrogen, Carlsbad, CA, USA). Fortyeight to 96 clones were randomly picked from each library for sequence analysis. Plasmid DNAs were prepared using a QIAprep 96 Turbo Miniprep kit (Qiagen Inc. Valencia, CA, USA) according to the manufacturer's protocol. DNA sequencing was performed at Corixa using an ABI377 automated sequencer (Perkin Elmer/Applied Biosystems Division, Foster City, CA, USA), with M13 forward and reverse primers. DNA homology database searches were performed using the BLAST program.
Gene expression analysis by cDNA microarray A total of 2400 cDNA inserts from the SCL1, SCL3 and SCL4 subtracted cDNA libraries were PCR ampli®ed with M13 forward and reverse primers. The ampli®ed cDNA inserts were analysed visually on 1% agarose gels to ensure quality and quantity of the DNA prior to deposition onto 32 replicate glass slides (microarrays) using a Genetic Microsystems GMS 417 Arrayer according to the manufacturer's recommendations. Gene expression pro®les were obtained from 32 pairs of¯uorescently-labeled cDNA samples synthesized from poly(A) + RNA isolated from various lung tumors, normal lung and other normal tissues. Thē uorescently-labeled samples for hybridization were generated using a two-step process as described earlier (Hughes et al., 2001) . Brie¯y, 1 mg of poly(A) + RNA was ®rst converted into aminoallyl-modi®ed cDNA (aa-cDNA) during reverse transcription with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and then reacted with Nhydroxysuccinimide esters of Cy3 or Cy5 (Amersham Pharmacia Biotech, Piscataway, NJ, USA). In each case, as an internal control for reverse transcription (RT) and microarray hybridization sensitivity, a synthetic mRNA transcript (pE1a, Hughes et al., 2001) was spiked into each sample prior to reverse transcription. Likewise, as a coupling eciency control, an aminoallyl-modi®ed transcript (derived from pCAT; Promega, Madison, WI, USA) was spiked into each aa-cDNA sample. Hybridization of samples, imaging of microarrays and quanti®cation of microarray features were done as described earlier (Marton et al., 1998) , except that a GenePix 4000A (Axon Instruments, Union City, CA, USA) microarray scanner was used. Hybridization intensity of each spot was normalized to the mean intensity of all non-control spots for each channel. Quality of hybridization data was evaluated using standard metrics such as mean signal to noise ratio (SNR) for all cDNA spots, SNR for each individual spot, spot morphology and ability to detect spiked in transcripts. The reproducibility of this method was ensured by including 16 ubiquitously expressed genes as control cDNA elements deposited at multiple locations on the microarray.
Quantitative real-time RT ± PCR
Quantitative real-time RT ± PCR reactions were performed on a GeneAmp 1 5700 sequence detection system using the SYBR 1 Green I dye method for Real-Time PCR (Perkin Elmer/Applied Biosystems Division, Foster City, CA, USA). To compare the relative level of gene expression in multiple tissue samples, a panel of 36 cDNAs was constructed using total RNA from SCLC tumors, SCLC cell lines, metastatic atypical carcinoid, lung adenocarcinomas (pool of four tumor samples), squamous cell lung carcinomas (pool of four tumor samples), normal lung, and other normal tissues. Total RNA was treated with DNase I (Invitrogen, Carlsbad, CA, USA) to remove genomic DNA contamination before cDNA synthesis. Mock cDNA synthesis reactions were performed, without reverse transcriptase, using 5 mg of DNase treated total RNA in a ®nal volume of 100 ml. Two ml of the mock cDNA reaction was used in a 25 ml b-actin PCR reaction to verify the absence of genomic DNA contamination. DNase treated total RNA samples veri®ed to be genomic DNA free were then used for the cDNA synthesis, which was carried out using 25 mg of DNase treated total RNA, by oligo-dT priming and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA), in a ®nal volume of 500 ml. Quantitative real-time RT ± PCR reactions were performed using gene speci®c primers to quantify the copy number of the gene of interest (GOI) in each cDNA sample. The realtime PCR reactions were performed in 25 ml volumes that include 2.5 ml of SYBR green buer, 2 ml of cDNA template and 2.5 ml each of the forward and reverse primers for the GOI. Mock reactions without cDNA template were also included to check for non-speci®c signal due to PCR artifacts such as primer dimerization. The cDNAs used for the PCR reactions were diluted 1 : 5 for each GOI and 1 : 50 for the bactin control. To quantitate the expression level of GOI in tumor and normal tissue samples, standard curves were generated using known copy numbers (20 to 2610 6 ) of GOI and b-actin cDNA, and GOI expression in each cDNA sample was normalized to the internal b-actin levels. The ®nal real-time RT-PCR results are reported as copy number of GOI per 1000 copies of b-actin.
